147 investment ideas from 91 funds across 91 stocks. Every thesis and quote on this page comes from a fund manager's own investor letter, not a 13F filing, so you can see the reasoning, risks and conviction behind each Healthcare & Biotechnology position.
LongLLYSep 2026
Eli Lilly is benefiting from strong demand for its diabetes and weight-loss therapies, which has materially changed its growth profile and generated substantial cash flow. The fund believes Lilly can reinvest that cash i
LongVRTXSep 2026
Vertex's cystic fibrosis franchise generates substantial cash flow that can be redeployed into new therapeutic areas. Management is using acquisitions and internal research to broaden the portfolio beyond the core franch
LongACHC
Khrom's thesis rests on the gap between Acadia's depressed near-term earnings and what it sees as substantially greater long-term earnings power. Acadia operates in behavioral healthcare, where demand is structurally ris
LongSOFW
Arauca's investment hypothesis is that Sofwave should be viewed as a utilisation platform rather than simply an equipment manufacturer. Usage-fee revenue grew 51% and reached a record 46% of sales, while equipment revenu
LongABT
Matrix initiated a new partial position in Abbott Laboratories after a significant share-price pullback. The fund likes Abbott's diversified healthcare businesses, recurring revenues and strong balance sheet. It also hig
LongUNH
Auxier believes UnitedHealth is using AI in a disciplined way to improve existing operations rather than making speculative infrastructure investments. Automation in administrative functions has saved significant labor h
LongSRTA
Immersion sees Strata as an overlooked remainco created after the former Blade sold its passenger e-mobility operation and retained its organ-transplant logistics and clinical-services business. Strata has grown rapidly,
LongRDVT
Immersion argues that Red Violet's identity-verification business has been wrongly treated as vulnerable to AI disruption. Its CORE platform is itself AI-driven and continuously builds and updates profiles using billions
LongFTRE
Fortrea is a contract research business that helps biotechnology and pharmaceutical customers design and execute clinical trials. The company was spun out of Labcorp in 2023 and is attempting to turn around its operation
LongTNET
Curreen added to TriNet because it viewed the company as an excellent business emerging from a difficult operating period at an unusually cheap valuation. Rapid changes in healthcare costs made insurance pricing difficul
LongREGN
The fund added to Regeneron because the stock ranked highly on cash flow and forecast earnings measures, two of LSV's most important valuation factors. Management has been repurchasing shares, which the fund views favora
Long041830
InBody is a category creator and global leader in body-composition measurement devices, with the US and Europe becoming its largest markets after years of geographic expansion. GLP-1 adoption is creating an additional de
“the company’s ability to convert today’s GLP-1 leadership into tomorrow’s medical breakthroughs makes it a compelling long-term investment.”
“the market continues to view Vertex primarily through the lens of its cystic fibrosis franchise”
“We believed most of these headwinds were transitory rather than structural.”
“My investment hypothesis rests on utilisation, that Sofwave is a utilization platform company.”
“We believe that the company is an attractive investment for the portfolio because of its recurring revenues, strong balance sheet, 54 years of dividend increases”
“Management reports that they are generating about $2 of value for every $1 spent on AI due to reductions in manual labor.”